About: Revefenacin   Goto Sponge  NotDistinct  Permalink

An Entity of Type : dul:ChemicalObject, within Data Space : wasabi.inria.fr associated with source document(s)

Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled. Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.

AttributesValues
type
label
  • Revefenacin
  • Rewefenacyna
  • Ревефенацин
comment
  • Ревефенацин - ингаляционный раствор для лечения хронической обструктивной болезни легких. Одобрен для применения: США (2018).
  • Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled. Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.
  • Rewefenacyna (łac. revefenacinum) – wielofunkcyjny organiczny związek chemiczny z grupy inhibitorów receptorów muskarynowych (M1–M5), długodziałający wziewny lek rozszerzający oskrzela w przewlekłej obturacyjnej chorobie płuc.
sameAs
topic
depiction
  • External Image
described by
dbp:drugbank
  • DB11855
dbp:kegg
  • D10978
dbp:medlineplus
  • a619009
dbp:tradename
  • Yupelri
Subject
dbo:wikiPageID
dbo:wikiPageRevisionID
dbo:wikiPageWikiLink
dbo:wikiPageExternalLink
is primary topic of
wasDerivedFrom
dbo:abstract
  • Ревефенацин - ингаляционный раствор для лечения хронической обструктивной болезни легких. Одобрен для применения: США (2018).
  • Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled. Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.
  • Rewefenacyna (łac. revefenacinum) – wielofunkcyjny organiczny związek chemiczny z grupy inhibitorów receptorów muskarynowych (M1–M5), długodziałający wziewny lek rozszerzający oskrzela w przewlekłej obturacyjnej chorobie płuc.
dbo:thumbnail
dbp:c
dbp:h
dbp:n
dbp:width
dbp:dailymedid
  • Revefenacin
dbp:atcPrefix
  • R03
dbp:atcSuffix
  • BB08
dbp:legalUs
  • Rx-only
dbp:casNumber
dbp:chemspiderid
dbp:o
dbp:pubchem
dbp:routesOfAdministration
dbp:smiles
  • CNCC4=CC=CCN5CCCCN
dbp:stdinchi
dbp:stdinchikey
  • FYDWDCIFZSGNBU-UHFFFAOYSA-N
dbp:unii
  • G2AE2VE07O
dbo:alternativeName
  • Yupelri
dbo:casNumber
  • 864750-70-9
dbo:drugbank
  • DB11855
dbo:fdaUniiCode
  • G2AE2VE07O
dbo:kegg
  • D10978
dbo:medlinePlus
  • a619009
dbo:pubchem
  • 11753673
dbo:wikiPageLength
dbp:wikiPageUsesTemplate
is sameAs of
is topic of
is dbo:wikiPageWikiLink of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software